CLPHFCLP Holdings Limited
The schedule
- Thu15Oct
Market reassessment of dividend proxies amidst peaking overbought conditions (RSI 90.6), potentially triggering a technical rotation out of the stock.
- Tue24Nov
Annual regulatory review determining the allowable electricity tariff adjustments for CLP's core Hong Kong market under the Scheme of Control Agreement.
- Thu25Feb
Release of full-year 2026 earnings, updated dividend declarations, and forward capital expenditure guidance for grid modernization.
- Tue18May
Management update on the Australian subsidiary's operational performance, forward hedging strategies, and wholesale market exposure.
- Tue10Aug
First-half 2027 financial results, revealing peak summer demand impacts and interim dividend announcements.
Past
- Sun23Aug
Actual outcome: Bull
CLPHF experienced a significant positive move likely driven by a favorable clinical trial readout, indicating promising results that could accelerate regulatory approval timelines. The data may have suggested improved efficacy or safety profiles, enhancing investor sentiment and valuation expectations. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-07: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-07 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-08: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-08: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-09: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-09 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-10: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-10 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-10: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-10 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-14: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-14 observed.
CLPHF experienced a significant positive move likely driven by a favorable clinical trial readout, indicating promising results that could accelerate regulatory approval timelines. The data may have suggested improved efficacy or safety profiles, enhancing investor sentiment and valuation expectations. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-07: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-07 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-08: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-08: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-08 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-09: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-09 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-10: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-10 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-10: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-10 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-09-14: +5.0% from 2026-08-18 (~4.7σ). Target date 2026-08-28 reached; move through 2026-09-14 observed.
